The development of novel peptide HNE inhibitors could be beneficial for the treatment of chronic obstructive pulmonary disease, acute lung injury, pulmonary fibrosis and disorders caused by COVID-19 infection, such as acute respiratory distress syndrome. This evidence concerns the gene ELANE and pulmonary fibrosis.